Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel B Luty

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The Journal of Biological Chemistry|January 10, 2014
Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerizationJulia E Maxson, Samuel B Luty, Jason D MacManiman, et al.
Journal of Hematology & Oncology|November 28, 2025
Retraction Note: Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targetsDeepika Kanojia, Manoj Garg, Jacqueline Martinez, et al.
Experimental Hematology|October 14, 2015
JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation modelStefan A Brooks, Samuel B Luty, Hew Yeng Lai, et al.
Journal of Hematology & Oncology|November 15, 2017
Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targetsDeepika Kanojia, Manoj Garg, Jacqueline Martinez, et al.
Blood|October 2, 2013
The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibitionAngela G Fleischman, Julia E Maxson, Samuel B Luty, et al.
Science Signaling|July 19, 2018
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemiaChelsea Jenkins, Samuel B Luty, Julia E Maxson, et al.
Cancer Research|June 3, 2015
Therapeutically Targetable ALK Mutations in LeukemiaJulia E Maxson, Monika A Davare, Samuel B Luty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2015
The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618IJulia E Maxson, Samuel B Luty, Jason D MacManiman, et al.
Cancer Research|December 19, 2015
Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic AnalysisJulia E Maxson, Melissa L Abel, Jinhua Wang, et al.
Blood|August 24, 2011
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasmsAngela G Fleischman, Karl J Aichberger, Samuel B Luty, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The Journal of Biological Chemistry|January 10, 2014
Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerizationJulia E Maxson, Samuel B Luty, Jason D MacManiman, et al.
Journal of Hematology & Oncology|November 28, 2025
Retraction Note: Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targetsDeepika Kanojia, Manoj Garg, Jacqueline Martinez, et al.
Experimental Hematology|October 14, 2015
JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation modelStefan A Brooks, Samuel B Luty, Hew Yeng Lai, et al.
Journal of Hematology & Oncology|November 15, 2017
Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targetsDeepika Kanojia, Manoj Garg, Jacqueline Martinez, et al.
Blood|October 2, 2013
The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibitionAngela G Fleischman, Julia E Maxson, Samuel B Luty, et al.
Science Signaling|July 19, 2018
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemiaChelsea Jenkins, Samuel B Luty, Julia E Maxson, et al.
Cancer Research|June 3, 2015
Therapeutically Targetable ALK Mutations in LeukemiaJulia E Maxson, Monika A Davare, Samuel B Luty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2015
The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618IJulia E Maxson, Samuel B Luty, Jason D MacManiman, et al.
Cancer Research|December 19, 2015
Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic AnalysisJulia E Maxson, Melissa L Abel, Jinhua Wang, et al.
Blood|August 24, 2011
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasmsAngela G Fleischman, Karl J Aichberger, Samuel B Luty, et al.
Pageof 1